Agilent's CrossLab segment is becoming the quiet efficiency layer for regulated pharma labs: services, consumables, software, automation, and asset monitoring. The proof gate is whether CrossLab can keep growing while margin stays strong.
References
Sources used in this report
Company earnings releaseAgilent Reports Second-Quarter Fiscal Year 2026 Financial Results2026-05-27 · Q2 revenue, guidance, CrossLab revenue, CrossLab margin, pharma and biotech market data.Company supplemental financialsAgilent Q2 FY2026 financial information2026-05-27 · Detailed Q2 revenue by market and region.SEC filingAgilent Q2 FY2026 Form 10-Q2026-06-01 · Latest filed quarterly report for the April 30, 2026 quarter.SEC filingAgilent FY2025 Form 10-K2025-12-22 · CrossLab segment description, vendor-neutral portfolio, FY2025 segment revenue and margin, pharma growth drivers.Company product pageAgilent CrossLab Connect2026-06-05 · Digital services, lab economics, uptime, and IoT/analytics context.Company product pageAgilent CrossLab Connect Asset Monitoring2026-06-05 · Utilization monitoring, workload balancing, capital planning, productivity, and bottleneck claims.